NCT05253131 2026-02-11
Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas
University of Alabama at Birmingham
Phase 2 Not yet recruiting
Clinical Trials
10 trialsNCT06712433 2026-02-09
CONCERTO
University of Pittsburgh
Phase 2 Not yet recruiting
NCT07342322 2026-01-15
A Prospective, Multicenter, Open-label, Single-arm Phase II Clinical Study Evaluating the Efficacy and Safety of Spatially Fractionated Radiotherapy Combined With the PraG Strategy for the Treatment of Soft Tissue Sarcoma
First Affiliated Hospital of Guangxi Medical University
Phase 2 Not yet recruiting
NCT07205185 2025-10-03
A Multicenter, Single-arm, Prospective Phase II Clinical Study of Epalrotokewali Combined With Eribulin, Anlotinib, and Radiotherapy for the Treatment of Patients With Advanced Soft Tissue Sarcoma.
Fudan University
Phase 2 Not yet recruiting
NCT07048184 2025-07-09
SUNDIAL
NHS Greater Glasgow and Clyde
Phase 2 Not yet recruiting
NCT06476704 2025-02-04
PRACTISS
Institut de cancérologie Strasbourg Europe
Phase 2 Not yet recruiting
NCT06694324 2024-11-19
First-line Treatment of Advanced/unresectable DDLPS
Fudan University
Phase 2 Not yet recruiting
NCT06551896 2024-08-13
Pemigatinib and Immune Checkpoint Inhibitor Treated FGFR1/2/3 Alteration Advanced Solid Tumor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Not yet recruiting
NCT06500091 2024-07-15
TQB2916 Injection Combined With Chemotherapy or Penpulimab Injection in the Treatment of Solid Tumors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2 Not yet recruiting
NCT04889742 2023-12-26
HETERERO
Charite University, Berlin, Germany
Phase 2 Not yet recruiting